Genesis Health System
Genesis Health System was paid $2.35M by Medicaid between Jan 2018 and Dec 2024, across 95 billing codes. Its largest line is 97110, Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion — 53% of everything it billed.
SILVIS, IL 61282
Next to other Ambulance providers in Illinois
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 14,975 | $548K | |
| 2019 | 26,377 | $742K | |
| 2020 | 12,921 | $333K | |
| 2021 | 10,360 | $334K | |
| 2022 | 7,054 | $269K | |
| 2023 | 4,307 | $93K | |
| 2024incomplete | 1,888 | $27K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 53% | 12,838 | 2,003 | $1.24M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 21% | 12,047 | 11,694 | $504K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 6.0% | 1,927 | 1,889 | $141K |
| 97161 | 4.2% | 942 | 618 | $99K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2.3% | 2,970 | 2,920 | $54K |
| 83655 | 1.6% | 3,448 | 3,340 | $38K | |
| 80053 | Comprehensive metabolic panel | 1.1% | 4,740 | 4,258 | $26K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 448 | 430 | $23K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,366 | 2,201 | $19K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 931 | 854 | $18K |
| 97162 | <1% | 166 | 95 | $18K | |
| 80061 | Lipid panel | <1% | 2,564 | 2,444 | $16K |
83 more codes
| 86738 | <1% | 1,546 | $15K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,114 | $15K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,113 | $14K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,115 | $11K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 838 | $11K |
| 87081 | <1% | 1,962 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,951 | $6K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 132 | $5K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 56 | $5K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 955 | $4K |
| 85027 | <1% | 1,787 | $4K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 22 | $4K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 459 | $3K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 2,595 | $3K |
| 84439 | <1% | 1,000 | $3K | |
| 87480 | <1% | 632 | $3K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 283 | $3K |
| 87510 | <1% | 632 | $2K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 467 | $2K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 28 | $2K |
| 87186 | <1% | 435 | $2K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 36 | $2K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 47 | $2K |
| A0425 | Ground mileage, per statute mile | <1% | 132 | $2K |
| 85018 | <1% | 1,205 | $1K | |
| 87340 | <1% | 542 | $1K | |
| 87660 | <1% | 619 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 761 | $983.62 |
| 99284 | Emergency room visit (serious) | <1% | 12 | $931.52 |
| 86580 | <1% | 327 | $927.08 | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 108 | $874.71 |
| 86787 | <1% | 384 | $863.20 | |
| 86480 | <1% | 24 | $859.30 | |
| 86592 | <1% | 1,013 | $750.43 | |
| 87400 | <1% | 262 | $687.27 | |
| 86141 | <1% | 133 | $682.29 | |
| 99283 | Emergency room visit (moderate) | <1% | 13 | $638.52 |
| 86901 | <1% | 581 | $637.81 | |
| 81001 | <1% | 1,333 | $634.57 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 221 | $634.35 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 17 | $583.78 |
| 86762 | <1% | 484 | $531.33 | |
| 82950 | <1% | 569 | $500.90 | |
| 82607 | <1% | 114 | $492.53 | |
| 87581 | <1% | 14 | $480.76 | |
| 86850 | <1% | 576 | $472.09 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 12 | $452.64 |
| 85610 | <1% | 418 | $449.26 | |
| 80076 | <1% | 67 | $376.96 | |
| 86900 | <1% | 578 | $307.90 | |
| 82728 | <1% | 212 | $289.71 | |
| 83615 | <1% | 234 | $213.15 | |
| 87070 | <1% | 106 | $196.82 | |
| 83540 | <1% | 220 | $168.92 | |
| 83735 | <1% | 292 | $162.83 | |
| 83550 | <1% | 114 | $151.83 | |
| 81003 | <1% | 212 | $112.40 | |
| 84702 | <1% | 45 | $96.17 | |
| 83718 | <1% | 12 | $88.11 | |
| 87420 | <1% | 16 | $84.04 | |
| 84156 | <1% | 190 | $72.80 | |
| 82570 | <1% | 98 | $72.63 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 13 | $54.92 |
| 82947 | <1% | 86 | $53.94 | |
| 82465 | <1% | 12 | $46.75 | |
| 84460 | <1% | 47 | $40.39 | |
| 83021 | <1% | 14 | $35.58 | |
| 87077 | <1% | 73 | $26.55 | |
| 82248 | <1% | 27 | $24.66 | |
| 82977 | <1% | 29 | $23.74 | |
| 76937 | <1% | 23 | $23.11 | |
| 85007 | <1% | 50 | $22.65 | |
| 84450 | <1% | 29 | $17.22 | |
| 86337 | <1% | 15 | $17.22 | |
| 82565 | <1% | 13 | $13.62 | |
| 82247 | <1% | 12 | $12.11 | |
| 82043 | <1% | 30 | $11.52 | |
| 85660 | <1% | 14 | $9.08 | |
| 85730 | <1% | 12 | $8.58 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 0% | 201 | $0.00 |
| 36416 | 0% | 18 | $0.00 | |
| 99001 | 0% | 108 | $0.00 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 194 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Genesis Health System | Davenport, IA | $9.12M |
| Genesis Health System | Silvis, IL | $4.03M |
| Genventures, INC. | Davenport, IA | $3.34M |
| Genesis Health System | De Witt, IA | $1.95M |
| Genventures, INC. | Davenport, IA | $246K |
| Central Utah Foot Clinic, LLC | Provo, UT | $39K |
| Genesis Health System | Erie, IL | $21K |
| Genventures, INC. | Moline, IL | $14K |
| Genventures, INC. | Davenport, IA | $8K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.